%0 Journal Article
%T Could Surgery Improve Survival in Patients with Advanced Endometrial Cancer?
%A Mervat Ali Mohamed Elsersy
%J Open Journal of Obstetrics and Gynecology
%P 832-841
%@ 2160-8806
%D 2022
%I Scientific Research Publishing
%R 10.4236/ojog.2022.128070
%X <strong>Background:</strong><span><span><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\"> Patients with endometrial cancer are mostly diagnosed at an early stage.
But unfortunately 10% to 15% of endometrial cancer patients will present with
advanced-stage disease, and hence poorer prognosis. When disease is primarily
intraperitoneal, cytoreduction to &lt;2 cm has also been correlated with better
survival, with the maximum benefit in patients who can be </span><span><span style=\"font-family:Verdana;\">reduced to no visible disease remaining. </span><b><span style=\"font-family:Verdana;\">Aim:</span></b><span style=\"font-family:Verdana;\"> Of the work is to detect the </span></span><span style=\"font-family:Verdana;\">survival rate benefits of primary surgery
in patients with advanced endometrial cancer at gynecologic oncology unit in El
Shatby Maternity University Hospital. </span><b><span style=\"font-family:Verdana;\">Methods</span></b> <b><span style=\"font-family:Verdana;\">and</span></b> <b><span style=\"font-family:Verdana;\">Materials:</span></b><span style=\"font-family:Verdana;\"> Retrospective study was conducted on 102 patients diagnosed to have advanced
endometrial cancer FIGO (stage III/IV) in a duration of 4 years between 2016
and 2020 and had undergone cytoreductive surgery. The patients were further subdivided
into two groups: group 1 who underwent optimal cytoreduction with residual
disease less than or equal </span><span style=\"font-family:Verdana;\">1</span></span></span></span><span><span><span style=\"font-family:;\" \"=\"\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">cm visible lesion, and group</span></span></span><span><span><span style=\"font-family:;\" \"=\"\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">2 who had residual disease more than 1</span></span></span><span><span><span style=\"font-family:;\" \"=\"\"> </span></span></span><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\"><span style=\"font-family:Verdana;\">cm</span></span></span><span><span><span style=\"font-family:;\" \"=\"\"><span style=\"font-family:Verdana;\"> visible
lesion and they were followed to check the survival benefits. </span><b><span style=\"font-family:Verdana;\">Results: </span></b><span style=\"font-family:Verdana;\">The
mean of disease free survival in group: 1) patients was 2 years which was
significantly longer than
%K Endometrial Cancer
%K Chemotherapy
%K Survival
%K Upfront Surgery
%K Radiotherapy
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=119405